Literature DB >> 7559624

Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element.

H Inoue1, C Yokoyama, S Hara, Y Tone, T Tanabe.   

Abstract

There exist two distinct isozymes of prostaglandin-endoperoxide synthase (PES). PES-2 mRNA is synergistically induced by lipopolysaccharide (LPS) and 12-O-tetradecanoylphorbol-13-acetate (TPA) in bovine arterial endothelial cells. On the other hand, PES-1 mRNA is constitutively expressed under these conditions. Therefore, the promoter activities of the human genes for PES-1 and -2 in bovine arterial endothelial cells were examined. The 5'-flanking region of the human PES-2 gene (nucleotides -327 to +59) showed promoter activity inducible by LPS and TPA using transient transfection analysis, whereas that of the PES-1 gene (nucleotides -1010 to +69) showed constitutive promoter activity. Destruction of both consensus sequences for the nuclear factor responsible for the interleukin-6 expression (NF-IL6) site (nucleotides -132 to -124) and the cyclic AMP response element (CRE) (nucleotides -59 to -53) of the human PES-2 gene markedly reduced the promoter activity (25%) of the PES-2 gene after combined treatment with LPS and TPA, although single destruction of the NF-IL6 site or the CRE slightly reduced the promoter activity (60 or 90%, respectively). Moreover, cotransfection experiments showed that a trans-acting factor, CCAAT enhancer binding protein delta (C/EBP delta), which binds to both the NF-IL6 site and the CRE, increased the promoter activity of the PES-2 gene mainly through the CRE. C/EBP delta mRNA was rapidly induced by LPS. Collectively, these results suggest that transcription of the PES-2 gene in vascular endothelial cells is regulated through combination of the NF-IL6 site and the CRE and that C/EBP delta functions as one of the trans-acting factors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7559624     DOI: 10.1074/jbc.270.42.24965

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  82 in total

Review 1.  Cyclo-oxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer's disease.

Authors:  P L McGeer
Journal:  Drugs Aging       Date:  2000-07       Impact factor: 3.923

2.  Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate.

Authors:  X M Xu; L Sansores-Garcia; X M Chen; N Matijevic-Aleksic; M Du; K K Wu
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

3.  The LIM domain protein LPP is a coactivator for the ETS domain transcription factor PEA3.

Authors:  Baoqiang Guo; Rosemary E Sallis; Amanda Greenall; Marleen M R Petit; Erik Jansen; Leonie Young; Wim J M Van de Ven; Andrew D Sharrocks
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

4.  Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling.

Authors:  Dan A Dixon; Neal D Tolley; Kristi Bemis-Standoli; Mark L Martinez; Andrew S Weyrich; Jason D Morrow; Stephen M Prescott; Guy A Zimmerman
Journal:  J Clin Invest       Date:  2006-09-21       Impact factor: 14.808

Review 5.  Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning.

Authors:  Roberto Bolli; Ken Shinmura; Xian-Liang Tang; Eitaro Kodani; Yu-Ting Xuan; Yiru Guo; Buddhadeb Dawn
Journal:  Cardiovasc Res       Date:  2002-08-15       Impact factor: 10.787

6.  Homeobox protein CDX2 reduces Cox-2 transcription by inactivating the DNA-binding capacity of nuclear factor-kappaB.

Authors:  Hiroyuki Mutoh; Hiroko Hayakawa; Hirotsugu Sakamoto; Kentaro Sugano
Journal:  J Gastroenterol       Date:  2007-09-25       Impact factor: 7.527

7.  Pro-inflammatory effects of early non-enzymatic glycated proteins in human mesothelial cells vary with cell donor's age.

Authors:  L Rodríguez-Mañas; C Sánchez-Rodríguez; S Vallejo; M El-Assar; C Peiró; V Azcutia; N Matesanz; C F Sánchez-Ferrer; J Nevado
Journal:  Br J Pharmacol       Date:  2006-10-30       Impact factor: 8.739

8.  Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.

Authors:  Chengyue Zhang; Zheng-Yuan Su; Ling Wang; Limin Shu; Yuqing Yang; Yue Guo; Douglas Pung; Chas Bountra; Ah-Ng Kong
Journal:  Biochem Pharmacol       Date:  2016-08-09       Impact factor: 5.858

9.  Inhibition of phorbol ester-induced mouse skin tumor promotion and COX-2 expression by celecoxib: C/EBP as a potential molecular target.

Authors:  Kyung-Soo Chun; Joydeb Kumar Kundu; Kwang-Kyun Park; Won-Yoon Chung; Young-Joon Surh
Journal:  Cancer Res Treat       Date:  2006-06-30       Impact factor: 4.679

10.  Effect of NS-398, a cyclooxygenase-2 selective inhibitor, on the cytotoxicity of cytotoxic T lymphocytes to ovarian carcinoma cells.

Authors:  Xinyan Wang; Yu Liang; Jun Wang; Min Wang
Journal:  Tumour Biol       Date:  2013-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.